Drug Targeting Organ-Specific Strategies

despite the available knowledge concerning these classical drugs, new evaluation of their use
as a part of drug targeting conjugates in a clinical setting seems obligatory.
7.8 Conclusions
The importance of the endothelium in the pathology of chronic inflammatory diseases is
nowadays appreciated. Therefore, the endothelium is an attractive target for therapeutic intervention.
Drug targeting strategies can be helpful in the treatment of these disorders. Endothelial
cells have the advantage of being easily accessible for drug targeting conjugates.
Preliminary results from in vitro studies demonstrated the potential of endothelium-directed
targeting strategies. This has stimulated current efforts to determine the therapeutic potential
of delivery modalities in in vivo models of chronic inflammation. Future studies will elucidate
whether intervention in endothelial activation is able to abrogate the vicious circle of
leucocyte recruitment and tissue damage, thereby improving the diseased state.
References
References 193
[1] Osborn L, In: Adhesion Molecules and Chemokines in Lymphocyte Trafficking (Ed. Hamann A),
pp. 217–236. Harwood Academic Publ. GmbH, Chur, 1997.
[2] Bell CJ, Wallace JL, BioDrugs 1997, 7, 273–284.
[3] Kluger MS, Johnson DR, Pober JS, J. Immunol. 1997, 158, 887–896.
[4] Panes J, Perry M, Granger DN, Br. J. Pharmacol. 1999, 126, 537–550.
[5] Malik AB, Lo SK, Pharmacol. Rev. 1996, 48, 213–229.
[6] Wuyts A, Struyf S, Proost P, Van Damme J, In: The Cytokine Network and Immune Function (Ed.
Theze J), pp. 125–145. Oxford University Press, Oxford, 1999.
[7] Newman PJ, J. Clin. Invest. 1999, 103, 5–9.
[8] Mantovani A, Sozzani S, Vecchi A, Introna M, Allavena P, Thromb. Haemost. 1997, 78, 406–414.
[9] Carlos TM, Harlan JM, Blood 1994, 84, 2068–2101.
[10] Bianchi E, Bender JR, Blasi F, Pardi R, Immunol. Today 1997, 18, 586–591.
[11] Gonzalez-Amaro R, Diaz-Gonzalez F, Sanchez-Madrid F, Drugs 1998, 56, 977–988.
[12] Orteu CH, Poulter LW, Rustin MH, Sabin CA, Salmon M, Akbar AN, J. Immunol. 1998, 161,
1619–1629.
[13] Daemen MA, van’t Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, Vandenabeele P,
Buurman WA, J. Clin. Invest. 1999, 104, 541–549.
[14] Brostoff J, Scadding GK, Male D, Roitt IM, Clinical Immunology. Mosby, London, 1994.
[15] Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ, Lab. Invest. 1991, 64,
313–320.
[16] Kriegsmann J, Keyszer GM, Geiler T, Lagoo AS, Lagoo-Deenadayalan S, Gay RE, Gay S, Arthritis
Rheum. 1995, 38, 750–754.
[17] Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE, J. Clin. Invest.
1998, 101, 1261–1272.
[18] Fox DA, Arch. Intern. Med. 2000, 160, 437–444.
[19] Amin AR, Attur M, Abramson SB, Curr. Opin. Rheumatol. 1999, 11, 202–209.
[20] Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle
PA, Neumeier D, J. Clin. Invest. 1996, 97, 1715–1722.
[21] Karmann K, Min W, Fanslow WC, Pober JS, J. Exp. Med. 1996, 184, 173–182.
[22] Mach F, Schonbeck U, Libby P, Atherosclerosis 1998, 137 (Suppl.), S89–S95.
[23] Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P,
Am. J. Pathol. 1999, 154, 229–238.
[24] Stallmach A, Strober W, Macdonald TT, Lochs H, Zeitz M, Immunol. Today 1998, 438–441.